Epilepsy is a chronic neurological disorder resulting from abnormal neuronal discharges in the brain. China has an estimated 10 million people with epilepsy, nearly half of whom are women of reproductive age. The disease significantly affects patients' fertility, pregnancy safety, and delivery outcomes, necessitating specialized cross-cycle health management, with most patients requiring continuous antiseizure medication during pregnancy. Lamotrigine (LTG), levetiracetam (LEV), and oxcarbazepine (OXC) are preferred pharmacological options during gestation due to their lower teratogenic risks. This review focuses on the holistic management of women with epilepsy (WWE) and the application of antiseizure medications (ASMs), aiming to provide evidence-based strategies for clinical practice.
